Very happy to share the results of our #ECPR program We treated >300 OHCA patients in the last 10 years in our cardiac arrest center in Milan 🇮🇹 17% survived, 57% of them with good neuro outcome Outcomes improved as the case volume increased 🧵 1/11 🔗 https://t.co/VthaIab3dj

We share our latest work published in @MRE_signavitae, in which we describe the results of > 3 years of intense research: the development of a new CPAP device designed for out-of-hospital emergency treatment of acute respiratory failure. 🔗 https://t.co/DNKgKUGBdf 1/3

This ILCOR systematic review informed 2025 ERC and AHA guidelines. 9/9

Future research should focus on carefully selected patients with a lower risk of hypoxic–ischemic brain injury. This aspect is extensively discussed in the manuscript. 8/

Selecting patients remains challenging. However, using only GCS at hospital arrival may be too restrictive, as few patients with good neurological outcome present with a GCS motor score of 4-5 at admission, potentially excluding those with recovery potential from MCS based solely

2) The DanGer-Shock RCT comparing a microaxial flow pump with standard care in AMI-CS showed improved 6-month survival but excluded comatose resuscitated patients (GCS ≤ 8), thereby selecting individuals at lower risk of irreversible brain injury more likely to benefit from MCS.

1) In patients with no or cardiac arrest duration < 10 minutes, MCS improved survival (56% vs 45%; RR 1.25 [95% CI, 1.06–1.47]); 5/

Although current evidence does not support the routine MCS in unselected patients with post-resuscitation shock, certain subgroups may benefit. 4/

Although data for complications in the cardiac arrest subgroup were very limited, tMCS use was associated with increased bleeding, hemolysis, vascular complications, and need for RRT. 3/

@Ilcor_org @shanfernands @MarkusSkrifvars @KateMBerg @IanR_Drennan We found that MCS did not improve survival at longest follow-up (46% with MCS vs 41% with standard care; RR 1.10 [95% CI, 0.94–1.29]) Bayesian analysis (RR 1.13 [95% CrI, 0.90–1.44]) showed an 88% posterior probability of any survival benefit (absolute risk difference >0%) and a

We just published in @ResusJournal a meta-analysis of MCS after ROSC While only 1 RCT addressed this topic only in CA pts, most RCTs of MCS in AMI-CS enrolled a high proportion of post-CA pts We pooled data from RCTs with available CA subgroups. https://t.co/YdSwfbcknz 1/

Hey #ReSS25! I know the travel might be a little challenging today- but all will be well once you arrive. We’re ready to host an amazing conference tackling the latest and greatest in resuscitation science. Safe travels to NOLA @3CPRCouncil

Just published in @ResusJournal a comprehensive scoping review (of 133 studies!) to map the existing evidence on post-resuscitation care after #ECPR 👉 Read the full text here https://t.co/T5Igc9vVm0 #CardiacArrest #Resuscitation

@alebelletti1 @JAMA_current @tscquizzato this is scaring! the setting is different but there is need for a definitive answer how many centers/colleagues are administering calcium after cardiac surgery? i guess a slowly infused low dose is safe, but a mRCT is warranted

1/ I.V. Calcium in cardiac surgery? ⬆️MAP and ⬇️HR for about 10 min ⬇️Response to catecholamines ⚠️No data on clinical outcomes! Our latest article: https://t.co/e6MYydIXba @SRAnesthesiaICU @giovannilandoni @LomivorotovV

3/ Calcium increases mortality in patients undergoing CPR for cardiac arrest according to a RCT published on @JAMA_current: https://t.co/F89Om3wV00 Is it safe in the perioperative period? @tscquizzato

Grateful for the opportunity to be invited to speak and share the stage with some of the leading experts at one of the world’s most important intensive care conferences. #ESICM #LIVES2025 @ESICM

Luchy week here is the new survey from organ donation in Italy by SIAARTI 🇮🇹 https://t.co/FZkOCYVk1Q

We are back and now on spotify! Join leading resuscitation experts as we go beyond the algorithm- unpacking the latest science, research and human factors that's shaping how we resuscitate - listen now @cliffreid @HawkmoonHEMS https://t.co/fxYY1IKW7z https://t.co/4qK3rt3FPr

Excited to be in Munich for the @ESICM #LIVES2025 Annual Congress. A fantastic opportunity to learn, meet colleagues, and exchange ideas!

"La cosa molto importante che abbiamo notato è che la maggior parte degli studi si stanno spostando nel trattamento delle malattie in fase precoce. Il focus in passato è stato di più sulla malattia metastatica. Oggi è di più sulla malattia precoce." @RobertoBurioni e Giuseppe